Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab

Choong kun Lee, Seung seob Kim, Saemi Park, Chan Kim, Su Jin Heo, Joon Seok Lim, Hyunki Kim, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Sohee Park, Minkyu Jung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: We aimed to determine and compare the predictive values of depth of response (DpR) and early tumor shrinkage (ETS) on long-term outcomes in gastric cancer patients treated with trastuzumab. Results: From a total of 368 computed tomography examinations, DpR and ETS were evaluated. DpR was a significant tumor-size metric in predicting PFS and OS, and showed better discriminatory ability (higher Ct indices, 0.6957 for PFS; 0.7191 for OS) than ETS. DpR ≥ 45% (vs. < 45%) was the optimal cutoffvalue, as it was best able to identify patients with longer PFS (median 9.0 vs. 6.3 months, hazard ratio [HR] = 0.608; 95% confidence interval [CI]: 0.335 to 1.104; P = 0.102) and OS (median 23.5 vs. 13.1 months, HR = 0.441; 95% CI: 0.203 to 0.955; P = 0.038). Materials and Methods: Sixty-one gastric cancer patients who received first-line trastuzumab-based chemotherapy were assessed for DpR and ETS. We employed Kaplan-Meier estimates, log-rank tests, Cox proportional hazards regression models, time-dependent receiver operating characteristics, and Youden's J index to evaluate and determine cutoffvalues of DpR and ETS as predictors of progression-free survival (PFS) and overall survival (OS). Conclusions: DpR and ETS were significant predictors of long-term outcomes in gastric cancer patients treated with first-line trastuzumab. Validation in prospective trials with larger patient populations is needed.

Original languageEnglish
Pages (from-to)31169-31179
Number of pages11
JournalOncotarget
Volume8
Issue number19
DOIs
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab'. Together they form a unique fingerprint.

  • Cite this

    Lee, C. K., Kim, S. S., Park, S., Kim, C., Heo, S. J., Lim, J. S., Kim, H., Kim, H. S., Rha, S. Y., Chung, H. C., Park, S., & Jung, M. (2017). Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 8(19), 31169-31179. https://doi.org/10.18632/oncotarget.16099